Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective
{{output}}
Background: Lebrikizumab and tralokinumab significantly treat moderate-to-severe atopic dermatitis. Nevertheless, pharmacoeconomic analyses and head-to-head clinical studies for both are lacking. This study aimed to compare the c... ...
